Stalevo 50 side effects, by duration, gender and age (a phase IV clinical study of FDA data)

female:

1. Anxiety
2. Coronary arterial stent insertion
3. Asthenia (weakness)
4. Balance disorder
5. Feeling drunk
6. General physical health deterioration (weak health status)
7. Abdominal pain
8. Accident
9. Aphagia (inability or refusal to swallow)
10. Back pain

male:

1. Drug ineffective
2. Aggression
3. Acute psychosis (period of mentally unstable behaviour)
4. Akinesia (loss of control of voluntary muscle movements)
5. Anaemia (lack of blood)
6. Anxiety
7. Apathy
8. Aphasia (damage to the parts of the brain that control language)
9. Arrhythmia (irregular heartbeat)
10. Asthenia (weakness)

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

1. Acute psychosis (period of mentally unstable behaviour)
2. Confusional state

50-59:

1. Abasia (inability to walk)
2. Hypoglycaemia (deficiency of glucose in the bloodstream)
3. Akinesia (loss of control of voluntary muscle movements)
4. Gait disturbance
5. General physical health deterioration (weak health status)
6. Hepatic enzyme increased

60+:

1. Anxiety
2. Balance disorder
3. Drug ineffective
4. Pneumonia
5. Arthropathy
6. Asthenia (weakness)
7. Burning sensation
8. Depression
9. Feeling drunk
10. Abdominal discomfort

< 1 month:

1. Hypoglycaemia (deficiency of glucose in the bloodstream)
2. Abasia (inability to walk)
3. Colonoscopy abnormal
4. Decreased appetite
5. Fall
6. Drug ineffective

1 - 6 months:

1. Asthenia (weakness)
2. Dyspepsia (indigestion)
3. General physical health deterioration (weak health status)
4. Speech disorder

6 - 12 months:

1. Anxiety
2. Aphagia (inability or refusal to swallow)
3. Drug effect prolonged

1 - 2 years:

1. Abdominal pain

2 - 5 years:

1. Confusional state

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Aggression
2. Anxiety
3. Asthenia (weakness)
4. Balance disorder
5. Coronary arterial stent insertion
6. Death
7. Pneumonia
8. Arthropathy
9. Blood pressure increased
10. Burning sensation